MedTrace Logo

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NCT07206849 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-04-08

No results posted yet for this study

Summary

The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets.

The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.

Conditions

  • High Grade Glioma (HGG) of the Brain With BRAF Aberration
  • High Grade Glioma (III or IV)
  • Diffuse Intrinsic Pontine Glioma
  • High Grade Glioma
  • WHO Grade 3 Glioma
  • WHO Grade 4 Glioma
  • Metastatic Brain Tumor

Interventions

DRUG

Tovorafenib

Tovorafenib will be given orally once weekly (QW) throughout each cycle.

Sponsors & Collaborators

  • Day One Biopharmaceuticals, Inc.

    collaborator INDUSTRY

  • Nationwide Children's Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2030-05-31
Completion
2037-05-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07206849 on ClinicalTrials.gov